SI1395553T1 - DERIVATI PIRALODINA KOT INHIBITORJI FAKTORJA Xa - Google Patents

DERIVATI PIRALODINA KOT INHIBITORJI FAKTORJA Xa

Info

Publication number
SI1395553T1
SI1395553T1 SI200230101T SI200230101T SI1395553T1 SI 1395553 T1 SI1395553 T1 SI 1395553T1 SI 200230101 T SI200230101 T SI 200230101T SI 200230101 T SI200230101 T SI 200230101T SI 1395553 T1 SI1395553 T1 SI 1395553T1
Authority
SI
Slovenia
Prior art keywords
inhibitors
factor
pyrrolidine derivatives
pyrrolidine
derivatives
Prior art date
Application number
SI200230101T
Other languages
English (en)
Inventor
Chuen GlaxoSmithKline CHAN
Julie Nicole Glaxosmithkline Hamblin
Henry Anderson Glaxosmithkline Kelly
Nigel Paul Glaxosmithkline King
Andrew Mcmurtrie Glaxosmithkline Mason
Vipulkumar Kantibhai GlaxoSmithKline PATEL
Stefan GlaxoSmithKline SENGER
Gita Punjabhai Glaxosmithkline Shah
Nigel Stephen Glaxosmithkline Watson
Helen Elisabeth Glaxosmithkline Weston
Caroline Glaxosmithkline Whitworth
Robert John Glaxosmithkline Young
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of SI1395553T1 publication Critical patent/SI1395553T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SI200230101T 2001-06-08 2002-06-06 DERIVATI PIRALODINA KOT INHIBITORJI FAKTORJA Xa SI1395553T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0114005.2A GB0114005D0 (en) 2001-06-08 2001-06-08 Chemical compounds
EP02738368A EP1395553B1 (en) 2001-06-08 2002-06-06 Pyrrolidine derivatives as factor xa inhibitors
PCT/GB2002/002721 WO2002100830A1 (en) 2001-06-08 2002-06-06 Pyrrolidine derivatives as factor xa inhibitors

Publications (1)

Publication Number Publication Date
SI1395553T1 true SI1395553T1 (sl) 2005-06-30

Family

ID=9916209

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200230101T SI1395553T1 (sl) 2001-06-08 2002-06-06 DERIVATI PIRALODINA KOT INHIBITORJI FAKTORJA Xa

Country Status (29)

Country Link
US (4) US7186717B2 (sl)
EP (1) EP1395553B1 (sl)
JP (1) JP4242274B2 (sl)
KR (1) KR100877245B1 (sl)
CN (1) CN1256324C (sl)
AR (1) AR036086A1 (sl)
AT (1) ATE289294T1 (sl)
AU (1) AU2002311451B2 (sl)
BR (1) BR0210207A (sl)
CA (1) CA2449629A1 (sl)
CO (1) CO5540285A2 (sl)
CZ (1) CZ20033325A3 (sl)
DE (1) DE60203006T2 (sl)
DK (1) DK1395553T3 (sl)
ES (1) ES2235050T3 (sl)
GB (1) GB0114005D0 (sl)
HK (1) HK1063471A1 (sl)
HU (1) HUP0400156A3 (sl)
IL (1) IL159195A0 (sl)
MX (1) MXPA03011384A (sl)
MY (1) MY136859A (sl)
NO (1) NO326689B1 (sl)
NZ (1) NZ530004A (sl)
PL (1) PL368082A1 (sl)
PT (1) PT1395553E (sl)
SI (1) SI1395553T1 (sl)
TW (1) TWI298719B (sl)
WO (1) WO2002100830A1 (sl)
ZA (1) ZA200309367B (sl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0130705D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Chemical compounds
GB0228533D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Crystalline form
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds
US20050119266A1 (en) * 2003-10-01 2005-06-02 Yan Shi Pyrrolidine and piperidine derivatives as factor Xa inhibitors
EP1637141B1 (en) 2004-09-21 2011-11-16 Trobio AB Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease
CN101087609B (zh) * 2004-10-26 2012-11-14 詹森药业有限公司 因子Xa化合物
WO2006110726A2 (en) * 2005-04-11 2006-10-19 Glaxo Group Limited Dosage formulations and methods of treatment and prevention
CN102380100A (zh) * 2005-09-22 2012-03-21 特罗比奥股份公司 稳定的蛋白酶组合物
JP5080476B2 (ja) * 2005-09-22 2012-11-21 トルービオ・アーベー 安定化プロテアーゼ組成物
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
JP6393310B2 (ja) * 2013-04-26 2018-09-19 サノフイＳａｎｏｆｉ ５−クロロ−チオフェン−２−カルボン酸［（ｓ）−２−［メチル−３−（２−オキソ−ピロリジン−１−イル）−ベンゼンスルホニルアミノ］−３−（４−メチル−ピペラジン−１−イル）−３−オキソ−プロプリル］アミドの酒石酸塩
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92011A0 (en) 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
DE4035961A1 (de) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4121947A1 (de) * 1991-07-03 1993-01-07 Basf Ag 2-(3-(4-amidino-phenyl))-propionsaeurederivate, ihre herstellung und verwendung
US5703208A (en) 1994-06-17 1997-12-30 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
CA2268281A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
AU726637B2 (en) 1996-12-13 2000-11-16 Aventis Pharmaceuticals Inc. Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
US6602864B1 (en) 1996-12-13 2003-08-05 Aventis Pharma Deutschland Gmbh Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
US6281227B1 (en) 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
IL135180A0 (en) 1997-09-30 2001-05-20 Daiichi Seiyaku Co Sulfonyl derivatives
KR20010034442A (ko) 1998-01-27 2001-04-25 아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드 치환된 옥소아자헤테로사이클릴 인자 Ｘａ 억제제
CN1298430A (zh) 1998-04-22 2001-06-06 昭和电工株式会社 表面被均匀氟化的粒状金属氧化物及其制造方法和用途
AU1926700A (en) 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase
EP1175405A4 (en) 1999-02-09 2002-05-15 Bristol Myers Squibb Co LACTAM INHIBITORS OF FACTOR Xa AND ASSOCIATED METHOD
AU3192500A (en) 1999-03-16 2000-10-04 C & C Research Laboratories Substituted proline derivatives and medicinal compositions containing the same
AU4431400A (en) 1999-05-12 2000-12-05 Japan As Represented By President Of National Cancer Center Anticancer agents containing ep1 antagonists as the active ingredient
AU773227B2 (en) 1999-07-28 2004-05-20 Aventis Pharmaceuticals Inc. Substituted oxoazaheterocyclyl compounds
WO2002060894A2 (en) 2001-01-30 2002-08-08 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of factor xa
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds
GB0228533D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Crystalline form

Also Published As

Publication number Publication date
KR100877245B1 (ko) 2009-01-07
HUP0400156A3 (en) 2008-10-28
ES2235050T3 (es) 2005-07-01
JP4242274B2 (ja) 2009-03-25
KR20040004706A (ko) 2004-01-13
GB0114005D0 (en) 2001-08-01
MY136859A (en) 2008-11-28
ATE289294T1 (de) 2005-03-15
MXPA03011384A (es) 2004-04-05
DK1395553T3 (da) 2005-06-06
BR0210207A (pt) 2004-08-03
EP1395553A1 (en) 2004-03-10
WO2002100830A1 (en) 2002-12-19
US20070155745A1 (en) 2007-07-05
DE60203006T2 (de) 2006-03-30
US7517879B2 (en) 2009-04-14
US20070142375A1 (en) 2007-06-21
EP1395553B1 (en) 2005-02-16
DE60203006D1 (de) 2005-03-24
CN1256324C (zh) 2006-05-17
US20070142374A1 (en) 2007-06-21
US7429587B2 (en) 2008-09-30
HUP0400156A2 (hu) 2004-07-28
CZ20033325A3 (cs) 2004-08-18
AU2002311451B2 (en) 2006-03-02
US7186717B2 (en) 2007-03-06
CA2449629A1 (en) 2002-12-19
TWI298719B (en) 2008-07-11
AR036086A1 (es) 2004-08-11
HK1063471A1 (en) 2004-12-31
JP2004537530A (ja) 2004-12-16
NZ530004A (en) 2005-08-26
ZA200309367B (en) 2004-08-02
PL368082A1 (en) 2005-03-21
CN1538955A (zh) 2004-10-20
PT1395553E (pt) 2005-06-30
NO20035440D0 (no) 2003-12-05
US20050107379A1 (en) 2005-05-19
IL159195A0 (en) 2004-06-01
CO5540285A2 (es) 2005-07-29
US7326785B2 (en) 2008-02-05
NO326689B1 (no) 2009-01-26

Similar Documents

Publication Publication Date Title
AU2002350217A8 (en) Glycinamides as factor xa inhibitors
HK1070352A1 (en) Indole-2-carboxamides as factor xa inhibitors
IL160693A0 (en) Lactam-containing compounds and derivatives thereof as factor xa inhibitors
IL169323A0 (en) Pyrazole-derivatives as factor xa inhibitors
AU2001273040A1 (en) Factor xa inhibitors
EP1684744A4 (en) PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS
EP1549646A4 (en) DERIVATIVES OF PIPERIDINE
AU2002365896A8 (en) Substituted amino methyl factor xa inhibitors
IL162765A0 (en) Piperidine derivatives
IL159195A0 (en) Pyrrolidine derivatives as factor xa inhibitors
SI1268419T1 (sl) Pirolidinski derivati, uporabni kot bax inhibitorji
IL162454A0 (en) Pyrrolidine-2-ones as factor xa inhibitors
ZA200508151B (en) Benzimidazole-derivatives as factor Xa inhibitors
EP1379245A4 (en) 1, 4, 5, 6-TETRAHYDROPYRAZOLO- 3, 4-C-PYRIDINE-7-ONE AS FACTOR XA HEMMER
PL350941A1 (en) Pyrazole-3-on-derivative as factor xa inhibitors
HK1089175A1 (en) Azaindole-derivatives as factor xa inhibitors
AU2003257637A1 (en) Proline derivatives
AU2003296393A1 (en) Factor xa inhibitors
AU2002222933A1 (en) Inhibitors of factor xa
AU2002325882A1 (en) Phenyl derivatives as factor Xa inhibitors
AU2002348501A1 (en) Factor xa inhibitor
AU2408802A (en) Novel carbapenem derivatives
HRP20050156A2 (en) Pyrrolidine derivatives as tryptase inhibitors
AU2002311432A1 (en) Pyrrolidin-2-one derivatives as inhibitors of factor xa
GB0104583D0 (en) Piperidine derivatives